NCT05122260View on ClinicalTrials.gov

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

January 27, 2022

Study Completion Date

February 14, 2022

Conditions
COVID-19 Prevention
Interventions
DRUG

Q-Griffithsin

intranasal spray administered as a single dose

OTHER

Placebo

intranasal spray administered as a single dose

Trial Locations (1)

40202

University of Louisville, Louisville

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Kenneth Palmer

OTHER

NCT05122260 - PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray | Biotech Hunter | Biotech Hunter